Cargando…

Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer

Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival. This comment highlights recent evidence on the epigenetic mechanisms underlying the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Goutam, Gupta, Kasmira, Kyprianou, Natasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895058/ https://www.ncbi.nlm.nih.gov/pubmed/36732329 http://dx.doi.org/10.1038/s41467-023-36253-1

Ejemplares similares

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
por: Cejas, Paloma, et al.
Publicado: (2021)

Mechanisms navigating the TGF-β pathway in prostate cancer
por: Cao, Zheng, et al.
Publicado: (2015)

Open questions: development of tumor cell heterogeneity and its implications for cancer treatment
por: Sommer, Lukas
Publicado: (2014)

Heterogeneity and cell fate flux in single human pancreatic islet cells
por: Ng, Natasha H. J., et al.
Publicado: (2018)

Anoikis in phenotypic reprogramming of the prostate tumor microenvironment
por: Nepali, Prerna R., et al.
Publicado: (2023)

Epigenetic mechanisms underlying prostate cancer radioresistance
por: Macedo-Silva, Catarina, et al.
Publicado: (2021)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression
por: Grant, Campbell M., et al.
Publicado: (2013)

Profiling Prostate Cancer Therapeutic Resistance
por: Wade, Cameron A., et al.
Publicado: (2018)

Open questions: Epigenetics and the role of heterochromatin in development
por: Gasser, Susan M
Publicado: (2013)

Brave new epigenomes: the dawn of epigenetic engineering
por: Köferle, Anna, et al.
Publicado: (2015)

Genetic and epigenetic studies of adiposity and cardiometabolic disease
por: Holmes, Michael V., et al.
Publicado: (2017)

The subacute toxicity and underlying mechanisms of biomimetic mesoporous polydopamine nanoparticles
por: Chen, Bang-Yao, et al.
Publicado: (2023)

Large-scale genomic analyses reveal alterations and mechanisms underlying clonal evolution and immune evasion in esophageal cancer
por: Lin, De-Chen
Publicado: (2023)

Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
por: Kyprianou, Natasha, et al.
Publicado: (2021)

Prostate tumor neuroendocrine differentiation via EMT: The road less traveled
por: Dicken, Haley, et al.
Publicado: (2019)

Prostate cancer grading, time to go back to the future
por: Egevad, Lars, et al.
Publicado: (2020)

Sympathetic nervous signaling dictates prostate cancer progression
por: Sigorski, D., et al.
Publicado: (2022)

Genetic and epigenetic analysis of schizophrenia in blood—a no-brainer?
por: Jaffe, Andrew E., et al.
Publicado: (2016)

A critical view on transgenerational epigenetic inheritance in humans
por: Horsthemke, Bernhard
Publicado: (2018)

Epigenetic convergence in the rising tide of opioid overdose deaths
por: Hays, Cameron F., et al.
Publicado: (2022)

Inflammation in prostate cancer progression and therapeutic targeting
por: Stark, Timothy, et al.
Publicado: (2015)

2D materials for future heterogeneous electronics
por: Lemme, Max C., et al.
Publicado: (2022)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

From discrimination and dis-ease to aging and disease-an epigenetic connection
por: Fiselier, Anna, et al.
Publicado: (2022)

Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance
por: Archer, Maddison, et al.
Publicado: (2020)

High altitude thrombosis—Evidence for underlying mechanisms from a large prospective longitudinal study
por: Wojta, Johann
Publicado: (2022)

Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders
por: Hoang, Ny, et al.
Publicado: (2018)

Managing COVID-19 importation risks in a heterogeneous world
por: Cauchemez, Simon, et al.
Publicado: (2021)

Breaking down walls in prostate cancer with the MURAL collection of patient-derived xenografts
por: Bevan, Charlotte L.
Publicado: (2021)

How I faced my prostate cancer: a molecular biologist’s perspective
por: Zuradelli, Monica, et al.
Publicado: (2021)

Novel epigenetic therapy for Th17 cell mediated autoimmune inflammatory diseases
por: Ho, Bo Man, et al.
Publicado: (2022)

Editorial Comment from Dr Suzuki to Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Suzuki, Motofumi
Publicado: (2020)

Editorial Comment from Dr Sakamoto to Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Sakamoto, Shinichi
Publicado: (2020)

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
por: Hu, Xiaoqian, et al.
Publicado: (2023)

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
por: Kahn, Barbara, et al.
Publicado: (2014)

Active surveillance should be considered for select men with Grade Group 2 prostate cancer
por: Pekala, Kelly R., et al.
Publicado: (2023)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
por: Gandaglia, Giorgio, et al.
Publicado: (2023)

Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome
por: Ware, Lorraine B
Publicado: (2020)

Public online reporting from a nationwide population‐based clinical prostate cancer register
por: Stattin, Pär, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aqtkb7abmenlh8338alauiqeut